Sage Therapeutics reported $1.6 million in net revenue from sales of ZULRESSO in Q3 2020, compared to $1.5 million for the same period in 2019. The company's clinical programs across three franchises remain on track, with key milestones anticipated over the next 12 to 18 months.
Zuranolone Phase 3 pivotal trials in major depression and postpartum depression are progressing well; expect to initiate dosing in CORAL Study in 4Q 2020
Continued execution across brain health franchises highlighted during 2nd annual FutureCast event
First patient dosed in PARADIGM Study investigating SAGE-718 in patients with Parkinson’s disease cognitive dysfunction
Company anticipates a cash balance of at least $550 million at end of 2020, which the Company anticipates will support operations into 2022 based on current operating plans.
Sage anticipates a cash balance of at least $550 million at end of 2020, which the Company anticipates will support operations into 2022 based on current operating plans.
Analyze how earnings announcements historically affect stock price performance